Atlas Trials

Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM

Clinical trial NCT05697510 · UNKNOWN

Trial details

NCT number
NCT05697510
Sponsor
Nantes University Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myeloid Leukemia (AML)
Start date
2023-03-16
Primary completion
2025-06-30
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.